一种小分子抗癌药物,用于长期起作用的溶酶体损伤
Shulin Zhao1, Qingjie Bai1, Guimin Xue2
1School of Pharmaceutical Sciences & Institute of Materia Medica, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China.
Acta pharmaceutica Sinica. B
|November 28, 2025
概括
这项研究引入了一种新型的长期溶酶体向抗癌药物 (LLAD),有效向癌细胞. 与思普拉丁相比,LLAD显示了长时间的溶酶体损伤和优越的体内抗癌效应.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药物开发 药物开发
背景情况:
- 溶解体是癌症治疗和克服耐药性的关键目标.
- 目前针对溶酶体的抗癌药物由于治疗时间短和效率低而面临局限性.
- 为改善癌症治疗,制定持续的溶酶体向策略至关重要.
研究的目的:
- 开发一种具有长期疗效的新型 lysosome 向抗癌药物.
- 研究粘合带方法对持续向溶酶体输送药物的潜力.
- 评估新药的抗癌作用和药物耐药性克服能力.
主要方法:
- 一种长期色素向抗癌药物 (LLAD) 的合成,其中包含一个向SLC38A9的部分和一个性成分.
- 用LLAD对HeLa细胞进行治疗,以评估溶酶体化和在多个细胞通道中保持药物.
- 在体内研究,以比较LLAD与西斯的长期抗癌作用.
主要成果:
- LLAD迅速化了溶解体,并且在溶解体中持续存在至通道15.
- 在HeLa细胞中通过长期的溶酶体损伤诱导了LLAD诱导的亡.
- 与西斯相比,LLAD在体内表现出更好的长期抗癌效果.
结论:
- 开发的粘合带方法使长期的溶酶体向和抑制成为可能.
- LLAD显示出作为癌症治疗和克服耐药性的治疗剂的显著潜力.
- 这项研究提供了一个有前途的候选药物LLAD,以及开发先进的溶酶体向抗癌疗法的新策略.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Delivery Pathways to the Lysosome
8.7K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.7K


